-
Mashup Score: 2The Bone-Marrow Transplant Revolution - 3 hour(s) ago
Finding a matched donor has always been the major challenge. A drug has solved that problem.
Source: www.theatlantic.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2The Bone-Marrow Transplant Revolution - 15 hour(s) ago
Finding a matched donor has always been the major challenge. A drug has solved that problem.
Source: www.theatlantic.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD - 25 day(s) ago
T-reg graft plus single-agent prophylaxis is preferred over T-reg graft alone for the prevention of acute GVHD.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation - 25 day(s) ago
Young adults (aged 18-25 years) are a distinct population with high rates of VOD.Disease-related factors predict for VOD in young adults (aged 18-25 years), and
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA - 25 day(s) ago
High-risk, untreated transplant-associated thrombotic microangiopathy after HCT has a dismal outcome due to multi-organ dysfunction.Early therapy with the C5 bl
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure for a variety of hematologic malignancies [1]. Historically, the availability of an HLA-matched donor was required for successful outcomes of HCT, to minimize the risk of graft rejection, graft-versus-host disease (GVHD), and nonrelapse mortality (NRM). An HLA-matched sibling donor (MSD) is the preferred donor, but this donor option is available in only 30% of patients [2]. In the absence of an MSD, an HLA-matched unrelated donor (MUD) may be identified through volunteer donor databases.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure for a variety of hematologic malignancies [1]. Historically, the availability of an HLA-matched donor was required for successful outcomes of HCT, to minimize the risk of graft rejection, graft-versus-host disease (GVHD), and nonrelapse mortality (NRM). An HLA-matched sibling donor (MSD) is the preferred donor, but this donor option is available in only 30% of patients [2]. In the absence of an MSD, an HLA-matched unrelated donor (MUD) may be identified through volunteer donor databases.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 1 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 1 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy - 1 month(s) ago
Chimeric antigen receptor T cells (CAR-T) targeting the B-cell maturation antigen (BCMA) have transformed the care of patients with relapsed/refractory (R/R) multiple myeloma (MM). Outcomes reported in pivotal studies have led to the approval of 2 anti-BCMA CAR-T therapy products, idecabtagene vicluecel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which have demonstrated significant improvements over prior standard of care in patients with triple-class exposed (TCE) RRMM [1–4]. The response rates to these therapies range between 73% and 98% [1,2,5].
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
Some sobering numbers “ Two-thirds of white people can find a fully matched registry donor, but that number drops to 23 percent for Black Americans and 41 percent for Asians or Pacific Islanders We need more donors to join @CanadasLifeline #bmtsm https://t.co/oXepkiezRG